A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain.

Intrathecal infusion of morphine using implantable pumps is an accepted practice for long-term management of chronic pain. Despite clinical benefit, development of tolerance and side-effects associated with intrathecal morphine has prompted investigators to explore alternative opioids such as the potent anilinopiperidine analogs, fentanyl, and sufentanil. Relevant preclinical and clinical literature from the MEDLINE database was used primarily for this review. In vitro, both compounds are stable in solution, but studies have not been conducted using implantable pumps under simulated use conditions (e.g., long-term stability at body temperature). Preclinical studies of limited duration have demonstrated efficacy, but safety-toxicology studies have been limited to intermittent boluses of sufentanil only. Few clinical reports on the use of intrathecal sufentanil or fentanyl for chronic pain are available. Although results confirm potency and efficacy with intrathecal administration, further studies are needed to support the long-term use of either opioid in chronic pain management.

[1]  Yuchiao Chang,et al.  Patient Selection and Trial Methods for Intraspinal Drug Delivery for Chronic Pain: A National Survey , 2005, Neuromodulation : journal of the International Neuromodulation Society.

[2]  J. Jamart,et al.  Stability of Sufentanil Citrate with Levobupivacaine HCl in NaCl 0.9% Infusion After Microwave Freeze–Thaw Treatment , 2004, The Annals of Pharmacotherapy.

[3]  O. A. Leon-Casasola,et al.  Interventional Procedures for Cancer Pain Management: When Are They Indicated? , 2004 .

[4]  S. Hassenbusch,et al.  Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panel. , 2004, Journal of pain and symptom management.

[5]  E. Kravitz,et al.  Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study , 2004, Pain.

[6]  S. Hassenbusch,et al.  Continuous intrathecal infusion of hydromorphone: safety in the sheep model and clinical implications. , 2004, Pain medicine.

[7]  H. Gerber Intrathecal morphine for chronic benign pain. , 2003, Best practice & research. Clinical anaesthesiology.

[8]  N. Rainov,et al.  Patient‐controlled Analgesia in Intrathecal Therapy for Chronic Pain: Safety and Effective Operation of the Model 8831 Personal Therapy Manager with a Pre‐implanted SynchroMed Infusion System , 2003, Neuromodulation : journal of the International Neuromodulation Society.

[9]  S. Hassenbusch,et al.  Safety of Chronic Intrathecal Morphine Infusion in a Sheep Model , 2003, Anesthesiology.

[10]  C. Sommer,et al.  Chronically Infused Intrathecal Morphine in Dogs , 2003, Anesthesiology.

[11]  M. Columb,et al.  Minimum Analgesic Doses of Fentanyl and Sufentanil for Epidural Analgesia in the First Stage of Labor , 2003, Anesthesia and analgesia.

[12]  G. Gourlay,et al.  Management of chronic intractable angina – spinal opioids offer an alternative therapy , 2003, Pain.

[13]  S. Hassenbusch,et al.  Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. , 2002, Pain medicine.

[14]  M. Westphal,et al.  Stability of a sufentanil-ropivacaine mixture in a glass and a PVC reservoir. , 2002, European journal of anaesthesiology.

[15]  V. C. Anderson,et al.  Stability and compatibility of hydromorphone hydrochloride in an implantable infusion system. , 2001, Journal of pain and symptom management.

[16]  J. Aldrete,et al.  Leg edema from intrathecal opiate infusions , 2000, European journal of pain.

[17]  S. Hassenbusch,et al.  Current practices in intraspinal therapy--a survey of clinical trends and decision making. , 2000, Journal of pain and symptom management.

[18]  C. Bernards,et al.  Comparative Spinal Distribution and Clearance Kinetics of Intrathecally Administered Morphine, Fentanyl, Alfentanil, and Sufentanil , 2000, Anesthesiology.

[19]  R. Miguel,et al.  Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? , 2000, Cancer control : journal of the Moffitt Cancer Center.

[20]  D. Doleys,et al.  The Effects of Long‐Term Intraspinal Infusion Therapy with Noncancer Pain Patients: Evaluation of Patient, Significant‐Other, and Clinic Staff Appraisals , 1999, Neuromodulation : journal of the International Neuromodulation Society.

[21]  E. Hamber,et al.  Intrathecal lipophilic opioids as adjuncts to surgical spinal anesthesia. , 1999, Regional anesthesia and pain medicine.

[22]  S. Hassenbusch,et al.  Cost Effectiveness of Intrathecal Therapy for Pain , 1999, Neuromodulation : journal of the International Neuromodulation Society.

[23]  P. Ravenscroft,et al.  Stability of midazolam and fentanyl in infusion solutions. , 1998, Journal of pain and symptom management.

[24]  S. Abram,et al.  Assessment of the Potency and Intrinsic Activity of Systemic versus Intrathecal Opioids in Rats , 1997, Anesthesiology.

[25]  E. Krames Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. , 1996, Journal of pain and symptom management.

[26]  S. Hassenbusch,et al.  Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. , 1995, Journal of pain and symptom management.

[27]  T. Yaksh,et al.  Differential right shifts in the dose-response curve for intrathecal morphine and sufentanil as a function of stimulus intensity , 1995, Pain.

[28]  M. Grafe,et al.  Spinal Delivery of Sufentanil, Alfentanil, and Morphine in Dogs: Physiologic and Toxicologic Investigations , 1994, Anesthesiology.

[29]  T. Schedl,et al.  Reexamination of C. elegans as a Model System for the Study of Volatile Anesthetic Mechanisms , 1994 .

[30]  L. Allen,et al.  Stability of bupivacaine hydrochloride, epinephrine hydrochloride, and fentanyl citrate in portable infusion-pump reservoirs. , 1993, American journal of hospital pharmacy.

[31]  N. Rawal,et al.  Behavioral and histopathologic effects following intrathecal administration of butorphanol, sufentanil, and nalbuphine in sheep. , 1991, Anesthesiology.

[32]  A. Dickenson Mechanisms of the analgesic actions of opiates and opioids. , 1991, British medical bulletin.

[33]  T. Hedner,et al.  The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. , 1991, Anesthesiology.

[34]  T. Yaksh,et al.  Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. , 1990, Anesthesiology.

[35]  L. Allen,et al.  Stability of fentanyl citrate and bupivacaine hydrochloride in portable pump reservoirs. , 1990, American journal of hospital pharmacy.

[36]  L. Allen,et al.  Stability of fentanyl citrate in 0.9% sodium chloride solution in portable infusion pumps. , 1990, American journal of hospital pharmacy.

[37]  T. Yaksh,et al.  Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. , 1989, The Journal of pharmacology and experimental therapeutics.

[38]  W. Boyle,et al.  VASOPRESSIN-INDUCED MYOCARDIAL ISCHEMIA AND REVERSAL WITH A SPECIFIC ANTAGONIST , 1986 .

[39]  T. Yaksh,et al.  Studies of the Pharmacology and Pathology of Intrathecally Administered 4‐Anilinopiperidine Analogues and Morphine in the Rat and Cat , 1986, Anesthesiology.

[40]  T. Reisine Opioid analgesics and antagonists , 1996 .

[41]  H. Adriaensen,et al.  Double blind comparison of fentanyl and sulfentanil in anesthesia. , 1976, Acta anaesthesiologica Belgica.